Using this model, we show that the SFK-mediated tyrosine phosphorylation of key Src-substrates is elevated at the infiltrating edge of aggressive GBM tumors, and that this SFK activity is further induced by treatment with the anti-angiogenic agent bevacizumab. The gene discussed is SRC; the disease is glioblastoma.